My Approach to Investing in CAR-T Drug Development: Cryoport (CYRX, Buy, $5.67)); Kite (KITE, Neutral, $104.34); Juno (JUNO, Neutral, $27.87), Novartis, (NVS, No opinion, $84.85)Wednesday, July 19, 2017 · 9:40 am |
|
SmithOnStocks Top Stock Picks for 2017, January 3, 2017Tuesday, January 3, 2017 · 10:18 am |
|
Updating My Investment Thinking on Kite (KITE, Neutral, $47.63) and Juno (JUNO, Neutrl, 17.86) in the Aftermath of the ASH MeetingWednesday, December 14, 2016 · 8:26 am |
|
My Current Investment Thinking on Kite (KITE, Neutral, $50.02) and Juno (JUNO, Neutral, $20.14) and the CAR-T Space as a WholeFriday, December 2, 2016 · 9:57 am |
|
A Non-Consensus, More Balanced Look at the CAR-T Development Efforts of Kite and Juno (Kite, $48.53: Juno, $30.42)Wednesday, July 13, 2016 · 4:44 pm |
|
Juno Therapeutics: FDA Quickly Lifts Its Clinical Hold on ROCKETWednesday, July 13, 2016 · 8:28 am |
|
Juno Therapeutics: Comments on Deaths in the ROCKET CAR-T Clinical Trial of JCAR-015(JUNO, $27.87)Friday, July 8, 2016 · 12:35 pm |
|
CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?Wednesday, April 29, 2015 · 8:57 am |
|
|
There are 8 reports on file. |
